echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Multiple Sclerosis Drugs or New Members: FDA Approves ANK-700 IND for the Treatment of Multiple Sclerosis.

    Multiple Sclerosis Drugs or New Members: FDA Approves ANK-700 IND for the Treatment of Multiple Sclerosis.

    • Last Update: 2020-10-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The U.S. Food and Drug Administration (FDA) has approved an IND application for the antigen-specific drug ANK-700 to treat multiple sclerosis (MS), Swiss biotech company Anokion SA announced recently.
    plans to launch a multi-center Phase I clinical trial for MS patients by the end of the year.
    is still a devastating disease," said Simon Cooper, chief medical officer of Anokion, a medical examiner.
    , the benefits of available interventions are limited and often do not address the underlying mechanisms that lead to disease exacerbation.
    an ANK-700 aims to re-integrate the immune system through a potential conversion method by utilizing natural immune tolerance pathways in the liver."
    in preclinical models, Anokion has demonstrated that its effective liver-targeted technology-induced to-resistant T-cell mechanisms can effectively prevent or reduce the pathological response of MS.
    In mouse models of MS, myelin-less protrusion glial glycosin (MOG) antigens targeting the liver induced pathological T cells to become unresponsive and missing, thus protecting them from disease attacks when they are to be tormented in active diseases.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.